Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ALPINE IMMUNE SCIENCES, INC.ALPN · Entity 90802 | Director · 10% owner | July 15, 2022 | July 19, 2022 |
| EXICURE, INC.XCUR · Entity 8068 | Director | July 06, 2020 | July 08, 2020 |
| Elicio Therapeutics, Inc.ELTX · Entity 299 | Director | August 31, 2026 | September 02, 2026 |
| IOVANCE BIOTHERAPEUTICS, INC.LBIO · Entity 2090 | Director | June 01, 2017 | June 05, 2017 |
| Serina Therapeutics, Inc.SER · Entity 9581 | Director | May 22, 2026 | June 22, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ALPINE IMMUNE SCIENCES, INC.
Report date July 15, 2022 · Filed July 19, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 238,126 |
Reported balance
After 2022-07-15 transaction · row 4
1 source rowRow 4 · 2022-07-15 · Exercise / conversion · Acquired 20,063 · Balance 238,126 |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.45 · Expires 2025-12-15 | Direct | 70,000 |
Reported balance
After 2022-07-15 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2022-07-15 · Exercise / conversion · Disposed 20,063 · Balance 70,000 F4: Pursuant to that certain Agreement and Plan of Merger and Reorganization (the "Merger Agreement"), dated as of April 18, 2017, by and among the Issuer, Nautilus Merger Sub, Inc. and the corporation then known as Alpine Immune Sciences, Inc. ("Old Alpine"), each share of Old Alpine common stock was converted into 0.4969 shares of the Issuer's common stock (the "Exchange Ratio"). Each option to purchase shares of Old Alpine outstanding and unexercised was assumed by the Issuer pursuant to the Merger Agreement and converted into an option, subject to vesting, to purchase shares of common stock of the Issuer, with the number of shares of the Issuer's common stock underlying such option and the exercise price for such option adjusted to reflect the Exchange Ratio. F5: The Reporting Person was initially granted an option to acquire 300,000 shares, 75,000 shares of which vested on May 25, 2016, and the remaining shares vested or vest in 36 substantially equal monthly installments starting on September 1, 2016, subject to the Reporting person's continued service with the Issuer and certain change of control provisions. |
| Common StockSEC Table I · non-derivative | IndirectBy Raj Venkatesan as UTMA custodian for Reid Coleman Venkatesan | 18,633 |
Reported balance
Holding disclosure · report date 2022-07-15 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 18,633 F1: The Reporting Person disclaims beneficial ownership of the shares of common stock reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F2: These shares are held by Raj Venkatesan as custodian for Reporting Person's sons under the California Uniform Transfers to Minors Act. |
| Common StockSEC Table I · non-derivative | IndirectBy Alpine ImmunoSciences, L.P. | 2,600,980 |
Reported balance
Holding disclosure · report date 2022-07-15 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 2,600,980 F1: The Reporting Person disclaims beneficial ownership of the shares of common stock reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F3: Alpine BioVentures GP, LLC is the general partner of Alpine ImmunoSciences, L.P. Dr. Venkatesan is a Managing Partner of Alpine BioVenture GP, LLC. Dr. Venkatesan is also a limited partner of Alpine ImmunoSciences, L.P. By virtue of such relationships, Dr. Venkatesan may be deemed to have voting and investment power with respect to the shares held by Alpine ImmunoSciences, L.P. and as a result may be deemed to have beneficial ownership of such shares. |
| Common StockSEC Table I · non-derivative | IndirectBy Raj Venkatesan as UTMA custodian for Nathaniel Graham Venkatesan | 18,633 |
Reported balance
Holding disclosure · report date 2022-07-15 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 18,633 F1: The Reporting Person disclaims beneficial ownership of the shares of common stock reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F2: These shares are held by Raj Venkatesan as custodian for Reporting Person's sons under the California Uniform Transfers to Minors Act. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person disclaims beneficial ownership of the shares of common stock reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
F2: These shares are held by Raj Venkatesan as custodian for Reporting Person's sons under the California Uniform Transfers to Minors Act.
F3: Alpine BioVentures GP, LLC is the general partner of Alpine ImmunoSciences, L.P. Dr. Venkatesan is a Managing Partner of Alpine BioVenture GP, LLC. Dr. Venkatesan is also a limited partner of Alpine ImmunoSciences, L.P. By virtue of such relationships, Dr. Venkatesan may be deemed to have voting and investment power with respect to the shares held by Alpine ImmunoSciences, L.P. and as a result may be deemed to have beneficial ownership of such shares.
F4: Pursuant to that certain Agreement and Plan of Merger and Reorganization (the "Merger Agreement"), dated as of April 18, 2017, by and among the Issuer, Nautilus Merger Sub, Inc. and the corporation then known as Alpine Immune Sciences, Inc. ("Old Alpine"), each share of Old Alpine common stock was converted into 0.4969 shares of the Issuer's common stock (the "Exchange Ratio"). Each option to purchase shares of Old Alpine outstanding and unexercised was assumed by the Issuer pursuant to the Merger Agreement and converted into an option, subject to vesting, to purchase shares of common stock of the Issuer, with the number of shares of the Issuer's common stock underlying such option and the exercise price for such option adjusted to reflect the Exchange Ratio.
F5: The Reporting Person was initially granted an option to acquire 300,000 shares, 75,000 shares of which vested on May 25, 2016, and the remaining shares vested or vest in 36 substantially equal monthly installments starting on September 1, 2016, subject to the Reporting person's continued service with the Issuer and certain change of control provisions.
EXICURE, INC.
Report date July 06, 2020 · Filed July 08, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 311,544 |
Reported balance
After 2020-07-06 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2020-07-06 · Exercise / conversion · Acquired 9,310 · Balance 311,544 |
| Common StockSEC Table I · non-derivative | Direct | 324,473 |
Reported balance
After 2020-07-06 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2020-07-06 · Exercise / conversion · Acquired 12,930 · Balance 324,473 |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.65 · Expires 2024-02-17 | Direct | 0 |
Reported balance
After 2020-07-06 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-07-06 · Exercise / conversion · Disposed 9,310 · Balance 0 F4: This option vested 25% on October 1, 2014, and the remaining 75% vested in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer and certain change of control provisions. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.03 · Expires 2025-04-28 | Direct | 0 |
Reported balance
After 2020-07-06 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2020-07-06 · Exercise / conversion · Disposed 12,930 · Balance 0 F5: This option vested in 48 substantially equal monthly installments from February 20, 2015, subject to the Reporting Person's continued service with the Issuer and certain change of control provisions. |
| Common StockSEC Table I · non-derivative | IndirectBy The Venkatesan-Louizides Trust | 190,957 |
Reported balance
Holding disclosure · report date 2020-07-06 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 190,957 F1: The Reporting Person is the trustee of the Venkatesan-Louizides Trust (the "Trust") and has voting or dispositive power over the shares held by the Trust. F2: The Reporting Person disclaims beneficial ownership of the shares of common stock reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectBy Ayer Special Situations Fund I, LP | 156,858 |
Reported balance
Holding disclosure · report date 2020-07-06 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 156,858 F2: The Reporting Person disclaims beneficial ownership of the shares of common stock reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F3: The Reporting Person is the managing director of the Ayer Special Situations Fund I, LP ("Ayer Fund") and has voting or dispositive power over the shares held by the Ayer Fund. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person is the trustee of the Venkatesan-Louizides Trust (the "Trust") and has voting or dispositive power over the shares held by the Trust.
F2: The Reporting Person disclaims beneficial ownership of the shares of common stock reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
F3: The Reporting Person is the managing director of the Ayer Special Situations Fund I, LP ("Ayer Fund") and has voting or dispositive power over the shares held by the Ayer Fund.
F4: This option vested 25% on October 1, 2014, and the remaining 75% vested in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer and certain change of control provisions.
F5: This option vested in 48 substantially equal monthly installments from February 20, 2015, subject to the Reporting Person's continued service with the Issuer and certain change of control provisions.
Elicio Therapeutics, Inc.
Report date August 31, 2026 · Filed September 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.70 · Expires 2036-08-31 | Direct | 21,750 |
Reported balance
After 2026-08-31 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-08-31 · Grant · Acquired 21,750 · Balance 21,750 F1: The stock option represents the annual non-employee director equity award to the Reporting Person and shall vest and become exercisable in full on the earlier of (A) August 31, 2027, the one-year anniversary of the date of grant, and (B) the annual meeting of the Issuer's stockholders held in 2027, subject to the Reporting Person continuing to provide services to the Issuer through such vesting date. No additional equity award will be made to the Reporting Person in connection with the 2026 annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option represents the annual non-employee director equity award to the Reporting Person and shall vest and become exercisable in full on the earlier of (A) August 31, 2027, the one-year anniversary of the date of grant, and (B) the annual meeting of the Issuer's stockholders held in 2027, subject to the Reporting Person continuing to provide services to the Issuer through such vesting date. No additional equity award will be made to the Reporting Person in connection with the 2026 annual meeting of stockholders.
IOVANCE BIOTHERAPEUTICS, INC.
Report date June 01, 2017 · Filed June 05, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.45 · Expires 2027-05-31 | Direct | 35,000 |
Reported balance
After 2017-06-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-06-01 · Grant · Acquired 35,000 · Balance 35,000 F1: These options are exercisable in four equal quarterly installments of 8,750 each following the date of grant. If the Reporting Person's service to the Issuer terminates before the expiration date, the option shares will be exercisable for two years following termination of service unless the Reporting Person is terminated for cause, in which case the options are terminated. |
Filing footnotes · ownership attribution and instrument terms
F1: These options are exercisable in four equal quarterly installments of 8,750 each following the date of grant. If the Reporting Person's service to the Issuer terminates before the expiration date, the option shares will be exercisable for two years following termination of service unless the Reporting Person is terminated for cause, in which case the options are terminated.
Serina Therapeutics, Inc.
Report date May 22, 2026 · Filed June 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 589 |
Reported balance
After 2026-05-22 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-05-22 · Purchase · Acquired 589 · Balance 589 F1: The share ownership amount has been adjusted to correct an administrative error in a prior Form 4 filed by the Reporting Person, which inadvertently reported 7,553 shares as direct ownership, rather than indirect ownership. |
| Common StockSEC Table I · non-derivative | IndirectThe Jay Venkatesan Legacy Trust | 231,705 |
Reported balance
After 2026-06-17 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2026-06-17 · Conversion · Acquired 224,152 · Balance 231,705 F2: Shares reflect the mandatory conversion at an adjusted Conversion Price of $2.25 of the Company's Series A Convertible Prefered Stock ("Series A Preferred") issued in connection with the April 2025 Private Placement. The Reporting Person was originally issued 96,525 shares of Series A Preferred that were converted into 222,222 shares of Common Stock and 1,930 shares that were issued for payment of accrued dividends. Shares were issued upon receipt of stockholder approval, which approval was obtained on June 17, 2026, thereby triggering the automatic conversion of the Series A Preferred into common stock. F1: The share ownership amount has been adjusted to correct an administrative error in a prior Form 4 filed by the Reporting Person, which inadvertently reported 7,553 shares as direct ownership, rather than indirect ownership. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.98 · Expires 2036-06-17 | Direct | 15,250 |
Reported balance
After 2026-06-17 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-17 · Grant · Acquired 15,250 · Balance 15,250 F3: The stock options will vest on the earlier of (i) the day before the next Annual Meeting or (ii) the one-year anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. |
| Series A Convertible Preferred StockSEC Table II · derivative / convertible security · Conversion / exercise price $5.18 | IndirectThe Jay Venkatesan Legacy Trust | 0 |
Reported balance
After 2026-06-17 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-06-17 · Conversion · Disposed 96,525 · Balance 0 F4: The Series A Convertible Preferred Stock is perpetual and therefore has no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: The share ownership amount has been adjusted to correct an administrative error in a prior Form 4 filed by the Reporting Person, which inadvertently reported 7,553 shares as direct ownership, rather than indirect ownership.
F2: Shares reflect the mandatory conversion at an adjusted Conversion Price of $2.25 of the Company's Series A Convertible Prefered Stock ("Series A Preferred") issued in connection with the April 2025 Private Placement. The Reporting Person was originally issued 96,525 shares of Series A Preferred that were converted into 222,222 shares of Common Stock and 1,930 shares that were issued for payment of accrued dividends. Shares were issued upon receipt of stockholder approval, which approval was obtained on June 17, 2026, thereby triggering the automatic conversion of the Series A Preferred into common stock.
F3: The stock options will vest on the earlier of (i) the day before the next Annual Meeting or (ii) the one-year anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.
F4: The Series A Convertible Preferred Stock is perpetual and therefore has no expiration date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 31, 2026 Filed Sep 2, 2026 20:02 UTC | Elicio Therapeutics, Inc. ELTX · Entity 299 | GrantStock Option (Right to Buy) · Derivative | 21,750 | $0.00 Strike: $2.70 | $0.00 |
DisclosureSEC source: 0001413350-26-000009 · wk-form4_1788379344.xml · derivative · entry 1 Venkatesan Jay · CIK 0001413350 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,750 Underlying: Common Stock · 21,750 shares Expires 2036-08-31 F1 · derivative.exercise_date: The stock option represents the annual non-employee director equity award to the Reporting Person and shall vest and become exercisable in full on the earlier of (A) August 31, 2027, the one-year anniversary of the date of grant, and (B) the annual meeting of the Issuer's stockholders held in 2027, subject to the Reporting Person continuing to provide services to the Issuer through such vesting date. No additional equity award will be made to the Reporting Person in connection with the 2026 annual meeting of stockholders. Read SEC document |
| June 17, 2026 Filed Jun 22, 2026 23:15 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | ConversionSeries A Convertible Preferred Stock · Derivative | 96,525 | $2.25 Strike: $5.18 | $217,181.25 |
DisclosureSEC source: 0001413350-26-000004 · wk-form4_1782170099.xml · derivative · entry 4 Venkatesan Jay · CIK 0001413350 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · The Jay Venkatesan Legacy Trust Disclosed balance after: 0 Underlying: Common Stock, $0.0001 par value · 222,222 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.expiration_date: The Series A Convertible Preferred Stock is perpetual and therefore has no expiration date. Read SEC document |
| June 17, 2026 Filed Jun 22, 2026 23:15 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | GrantStock Option (right to buy) · Derivative | 15,250 | $0.00 Strike: $1.98 | $0.00 |
DisclosureSEC source: 0001413350-26-000004 · wk-form4_1782170099.xml · derivative · entry 3 Venkatesan Jay · CIK 0001413350 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,250 Underlying: Common Stock · 15,250 shares Expires 2036-06-17 F3 · derivative.exercise_date: The stock options will vest on the earlier of (i) the day before the next Annual Meeting or (ii) the one-year anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. Read SEC document |
| June 17, 2026 Filed Jun 22, 2026 23:15 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | ConversionCommon Stock | 224,152 | $2.25 | $504,342.00 |
DisclosureSEC source: 0001413350-26-000004 · wk-form4_1782170099.xml · nonDerivative · entry 2 Venkatesan Jay · CIK 0001413350 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · The Jay Venkatesan Legacy Trust Disclosed balance after: 231,705 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: Shares reflect the mandatory conversion at an adjusted Conversion Price of $2.25 of the Company's Series A Convertible Prefered Stock ("Series A Preferred") issued in connection with the April 2025 Private Placement. The Reporting Person was originally issued 96,525 shares of Series A Preferred that were converted into 222,222 shares of Common Stock and 1,930 shares that were issued for payment of accrued dividends. Shares were issued upon receipt of stockholder approval, which approval was obtained on June 17, 2026, thereby triggering the automatic conversion of the Series A Preferred into common stock. F1 · balance_after: The share ownership amount has been adjusted to correct an administrative error in a prior Form 4 filed by the Reporting Person, which inadvertently reported 7,553 shares as direct ownership, rather than indirect ownership. Read SEC document |
| May 22, 2026 Filed Jun 22, 2026 23:15 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | PurchaseCommon Stock | 589 | $1.78 | $1,048.42 |
DisclosureSEC source: 0001413350-26-000004 · wk-form4_1782170099.xml · nonDerivative · entry 1 Venkatesan Jay · CIK 0001413350 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 589 F1 · balance_after: The share ownership amount has been adjusted to correct an administrative error in a prior Form 4 filed by the Reporting Person, which inadvertently reported 7,553 shares as direct ownership, rather than indirect ownership. Read SEC document |
| March 31, 2026 Filed Apr 21, 2026 19:31 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | GrantCommon Stock | 7,553 | $1.94 | $14,652.82 |
DisclosureSEC source: 0001413350-26-000002 · wk-form4_1776799907.xml · nonDerivative · entry 1 Venkatesan Jay · CIK 0001413350 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,553 F1 · shares: These shares of common stock were issued for payment of accrued dividends on the reporting individuals A Convertible Preferred Stock issued on April 8, 2025. Read SEC document |
| November 07, 2025 Filed Nov 11, 2025 00:57 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $3.91 | $0.00 |
DisclosureSEC source: 0001413350-25-000004 · wk-form4_1762822637.xml · derivative · entry 1 Venkatesan Jay · CIK 0001413350 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2035-11-07 F1 · derivative.exercise_date: The stock options will vest on the earlier of (i) the day before the next Annual Meeting or (ii) the one-year anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. Read SEC document |
| May 19, 2025 Filed May 20, 2025 20:07 UTC | Elicio Therapeutics, Inc. ELTX · Entity 299 | GrantStock Option (Right to Buy) · Derivative | 7,900 | $0.00 Strike: $5.84 | $0.00 |
DisclosureSEC source: 0001601485-25-000088 · wk-form4_1747771626.xml · derivative · entry 1 Venkatesan Jay · CIK 0001413350 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,900 Underlying: Common Stock · 7,900 shares Expires 2035-05-19 F1 · shares: The stock option shall vest and become exercisable in full on the earlier of (A) May 19, 2026, the one-year anniversary of the date of grant and (B) the next annual meeting of the Company's stockholders after the grant date, subject to the Reporting Person continuing to provide services to the Issuer through such vesting date. F1 · derivative.exercise_date: The stock option shall vest and become exercisable in full on the earlier of (A) May 19, 2026, the one-year anniversary of the date of grant and (B) the next annual meeting of the Company's stockholders after the grant date, subject to the Reporting Person continuing to provide services to the Issuer through such vesting date. Read SEC document |
| April 08, 2025 Filed Apr 10, 2025 20:03 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | GrantSeries A Convertible Preferred Stock · Derivative | 96,525 | $5.18 Strike: $5.18 | $499,999.50 |
DisclosureSEC source: 0001708599-25-000038 · wk-form4_1744315385.xml · derivative · entry 1 Venkatesan Jay · CIK 0001413350 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · The Jay Venkatesan Legacy Trust Disclosed balance after: 96,525 Underlying: Common Stock, $0.0001 par value · 96,525 shares Expires not disclosed F1 · derivative.expiration_date: The Series A Convertible Preferred Stock is perpetual and therefore has no expiration date. Read SEC document |
| February 12, 2025 Filed Feb 13, 2025 22:03 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $4.60 | $0.00 |
DisclosureSEC source: 0001708599-25-000021 · wk-form4_1739484224.xml · derivative · entry 1 Venkatesan Jay · CIK 0001413350 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2035-02-12 F1 · derivative.exercise_date: The stock options vest in substantially equal yearly installments beginning on the first anniversary of the grant date such that the stock options shall be fully vested on the third anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. Read SEC document |
| November 26, 2024 Filed Nov 29, 2024 12:39 UTC | Elicio Therapeutics, Inc. ELTX · Entity 299 | OtherWarrant to Purchase Common Stock · Derivative | 50,000 | $0.00 Strike: $0.01 | $0.00 |
DisclosureSEC source: 0001601485-24-000105 · wk-form4_1732883980.xml · derivative · entry 3 Venkatesan Jay · CIK 0001413350 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires not disclosed F3 · derivative.expiration_date: N/A Read SEC document |
| November 26, 2024 Filed Nov 29, 2024 12:39 UTC | Elicio Therapeutics, Inc. ELTX · Entity 299 | OtherCommon Stock | 50,000 | $0.01 | $500.00 |
DisclosureSEC source: 0001601485-24-000105 · wk-form4_1732883980.xml · nonDerivative · entry 1 Venkatesan Jay · CIK 0001413350 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 179,581 F1 · shares: On November 26, 2024, the Reporting Person exercised a pre-funded warrant to purchase an aggregate of 50,000 shares of the Issuer's common stock. Read SEC document |
| November 21, 2024 Filed Nov 25, 2024 12:35 UTC | Elicio Therapeutics, Inc. ELTX · Entity 299 | GrantStock Option (Right to Buy) · Derivative | 4,100 | $0.00 Strike: $5.12 | $0.00 |
DisclosureSEC source: 0001601485-24-000095 · wk-form4_1732538114.xml · derivative · entry 1 Venkatesan Jay · CIK 0001413350 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,100 Underlying: Common Stock · 4,100 shares Expires 2034-11-21 F1 · shares: The stock option shall vest and become exercisable in full on the earlier of (A) November 21, 2025, the one-year anniversary of the date of grant and (B) the next annual meeting of the Company's stockholders after the grant date, subject to the Reporting Person continuing to provide services to the Issuer through such vesting date. F1 · derivative.exercise_date: The stock option shall vest and become exercisable in full on the earlier of (A) November 21, 2025, the one-year anniversary of the date of grant and (B) the next annual meeting of the Company's stockholders after the grant date, subject to the Reporting Person continuing to provide services to the Issuer through such vesting date. Read SEC document |
| June 28, 2024 Filed Jul 3, 2024 01:53 UTC | Elicio Therapeutics, Inc. ELTX · Entity 299 | PurchasePre-Funded Warrants · Derivative | 50,000 | $4.99 Strike: $0.01 | $249,500.00 |
DisclosureSEC source: 0001140361-24-032293 · form4.xml · derivative · entry 8 Venkatesan Jay · CIK 0001413350 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires not disclosed F3 · derivative.exercise_date: Each Pre-Funded Warrant will be exercisable by the holder at any time on or after July 1, 2024 at an exercise price equal to $0.01 per share, subject to adjustments as provided under the terms of the Pre-Funded Warrant, subject to a post-exercise beneficial ownership limitation of 4.99%. F4 · derivative.expiration_date: The Pre-Funded Warrants do not have an expiration date. F5 · ownership.nature: The Reporting Person may be deemed to have shared voting and investment power over the trust which holds these securities. A Member of the Reporting Person's immediate family is the beneficiary of the trust which holds these securities. The Reporting Person disclaims beneficial ownership of the securities held by the trust which holds these securities except to the extent of his pecuniary interest therein, if any. Read SEC document |
| June 28, 2024 Filed Jul 3, 2024 01:53 UTC | Elicio Therapeutics, Inc. ELTX · Entity 299 | PurchaseCommon Warrants · Derivative | 50,000 | $0.00 Strike: $5.00 | $0.00 |
DisclosureSEC source: 0001140361-24-032293 · form4.xml · derivative · entry 7 Venkatesan Jay · CIK 0001413350 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires not disclosed F1 · derivative.exercise_date: Each Common Warrant will be exercisable by the holder at any time on or after July 1, 2024 at an exercise price equal to $5.00 per share, subject to adjustments as provided under the terms of the Common Warrant, subject to a post-exercise beneficial ownership limitation of 4.99%. F2 · derivative.expiration_date: The Common Warrants expire on July 1, 2029. F5 · ownership.nature: The Reporting Person may be deemed to have shared voting and investment power over the trust which holds these securities. A Member of the Reporting Person's immediate family is the beneficiary of the trust which holds these securities. The Reporting Person disclaims beneficial ownership of the securities held by the trust which holds these securities except to the extent of his pecuniary interest therein, if any. Read SEC document |
| June 28, 2024 Filed Jul 3, 2024 01:53 UTC | Elicio Therapeutics, Inc. ELTX · Entity 299 | PurchasePre-Funded Warrants · Derivative | 50,000 | $4.99 Strike: $0.01 | $249,500.00 |
DisclosureSEC source: 0001140361-24-032293 · form4.xml · derivative · entry 6 Venkatesan Jay · CIK 0001413350 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires not disclosed F3 · derivative.exercise_date: Each Pre-Funded Warrant will be exercisable by the holder at any time on or after July 1, 2024 at an exercise price equal to $0.01 per share, subject to adjustments as provided under the terms of the Pre-Funded Warrant, subject to a post-exercise beneficial ownership limitation of 4.99%. F4 · derivative.expiration_date: The Pre-Funded Warrants do not have an expiration date. F5 · ownership.nature: The Reporting Person may be deemed to have shared voting and investment power over the trust which holds these securities. A Member of the Reporting Person's immediate family is the beneficiary of the trust which holds these securities. The Reporting Person disclaims beneficial ownership of the securities held by the trust which holds these securities except to the extent of his pecuniary interest therein, if any. Read SEC document |
| June 28, 2024 Filed Jul 3, 2024 01:53 UTC | Elicio Therapeutics, Inc. ELTX · Entity 299 | PurchaseCommon Warrants · Derivative | 50,000 | $0.00 Strike: $5.00 | $0.00 |
DisclosureSEC source: 0001140361-24-032293 · form4.xml · derivative · entry 5 Venkatesan Jay · CIK 0001413350 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires not disclosed F1 · derivative.exercise_date: Each Common Warrant will be exercisable by the holder at any time on or after July 1, 2024 at an exercise price equal to $5.00 per share, subject to adjustments as provided under the terms of the Common Warrant, subject to a post-exercise beneficial ownership limitation of 4.99%. F2 · derivative.expiration_date: The Common Warrants expire on July 1, 2029. F5 · ownership.nature: The Reporting Person may be deemed to have shared voting and investment power over the trust which holds these securities. A Member of the Reporting Person's immediate family is the beneficiary of the trust which holds these securities. The Reporting Person disclaims beneficial ownership of the securities held by the trust which holds these securities except to the extent of his pecuniary interest therein, if any. Read SEC document |
| June 28, 2024 Filed Jul 3, 2024 01:53 UTC | Elicio Therapeutics, Inc. ELTX · Entity 299 | PurchasePre-Funded Warrants · Derivative | 50,000 | $4.99 Strike: $0.01 | $249,500.00 |
DisclosureSEC source: 0001140361-24-032293 · form4.xml · derivative · entry 4 Venkatesan Jay · CIK 0001413350 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires not disclosed F3 · derivative.exercise_date: Each Pre-Funded Warrant will be exercisable by the holder at any time on or after July 1, 2024 at an exercise price equal to $0.01 per share, subject to adjustments as provided under the terms of the Pre-Funded Warrant, subject to a post-exercise beneficial ownership limitation of 4.99%. F4 · derivative.expiration_date: The Pre-Funded Warrants do not have an expiration date. F5 · ownership.nature: The Reporting Person may be deemed to have shared voting and investment power over the trust which holds these securities. A Member of the Reporting Person's immediate family is the beneficiary of the trust which holds these securities. The Reporting Person disclaims beneficial ownership of the securities held by the trust which holds these securities except to the extent of his pecuniary interest therein, if any. Read SEC document |
| June 28, 2024 Filed Jul 3, 2024 01:53 UTC | Elicio Therapeutics, Inc. ELTX · Entity 299 | PurchaseCommon Warrants · Derivative | 50,000 | $0.00 Strike: $5.00 | $0.00 |
DisclosureSEC source: 0001140361-24-032293 · form4.xml · derivative · entry 3 Venkatesan Jay · CIK 0001413350 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires not disclosed F1 · derivative.exercise_date: Each Common Warrant will be exercisable by the holder at any time on or after July 1, 2024 at an exercise price equal to $5.00 per share, subject to adjustments as provided under the terms of the Common Warrant, subject to a post-exercise beneficial ownership limitation of 4.99%. F2 · derivative.expiration_date: The Common Warrants expire on July 1, 2029. F5 · ownership.nature: The Reporting Person may be deemed to have shared voting and investment power over the trust which holds these securities. A Member of the Reporting Person's immediate family is the beneficiary of the trust which holds these securities. The Reporting Person disclaims beneficial ownership of the securities held by the trust which holds these securities except to the extent of his pecuniary interest therein, if any. Read SEC document |
| June 28, 2024 Filed Jul 3, 2024 01:53 UTC | Elicio Therapeutics, Inc. ELTX · Entity 299 | PurchasePre-Funded Warrants · Derivative | 50,000 | $4.99 Strike: $0.01 | $249,500.00 |
DisclosureSEC source: 0001140361-24-032293 · form4.xml · derivative · entry 2 Venkatesan Jay · CIK 0001413350 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires not disclosed F3 · derivative.exercise_date: Each Pre-Funded Warrant will be exercisable by the holder at any time on or after July 1, 2024 at an exercise price equal to $0.01 per share, subject to adjustments as provided under the terms of the Pre-Funded Warrant, subject to a post-exercise beneficial ownership limitation of 4.99%. F4 · derivative.expiration_date: The Pre-Funded Warrants do not have an expiration date. Read SEC document |
| June 28, 2024 Filed Jul 3, 2024 01:53 UTC | Elicio Therapeutics, Inc. ELTX · Entity 299 | PurchaseCommon Warrants · Derivative | 50,000 | $0.00 Strike: $5.00 | $0.00 |
DisclosureSEC source: 0001140361-24-032293 · form4.xml · derivative · entry 1 Venkatesan Jay · CIK 0001413350 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires not disclosed F1 · derivative.exercise_date: Each Common Warrant will be exercisable by the holder at any time on or after July 1, 2024 at an exercise price equal to $5.00 per share, subject to adjustments as provided under the terms of the Common Warrant, subject to a post-exercise beneficial ownership limitation of 4.99%. F2 · derivative.expiration_date: The Common Warrants expire on July 1, 2029. Read SEC document |
| June 28, 2024 Filed Jan 2, 2025 21:05 UTC Amendment | Elicio Therapeutics, Inc. ELTX · Entity 299 | PurchasePre-Funded Warrants · Derivative | 50,000 | $4.99 Strike: $0.01 | $249,500.00 |
DisclosureSEC source: 0001601485-25-000002 · wk-form4a_1735851944.xml · derivative · entry 2 Venkatesan Jay · CIK 0001413350 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires not disclosed F4 · derivative.exercise_date: Each Pre-Funded Warrant will be exercisable by the holder at any time on or after July 1, 2024 at an exercise price equal to $0.01 per share, subject to adjustments as provided under the terms of the Pre-Funded Warrant, subject to a post-exercise beneficial ownership limitation of 4.99%. F5 · derivative.expiration_date: The Pre-Funded Warrants do not have an expiration date. F3 · ownership.direct: On July 2, 2024, the Reporting Person mistakenly filed a Form 4 reporting the acquisition of an additional 150,000 Common Warrants and 150,000 Pre-Funded Warrants. The Reporting Person is not the beneficial owner of such Common Warrants or Pre-Funded Warrants. As of January 2, 2025, the Reporting Person owned only the Common Warrants and Pre-Funded Warrants reported herein. Read SEC document |
| June 28, 2024 Filed Jan 2, 2025 21:05 UTC Amendment | Elicio Therapeutics, Inc. ELTX · Entity 299 | PurchaseCommon Warrants · Derivative | 50,000 | $0.00 Strike: $5.00 | $0.00 |
DisclosureSEC source: 0001601485-25-000002 · wk-form4a_1735851944.xml · derivative · entry 1 Venkatesan Jay · CIK 0001413350 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires not disclosed F1 · derivative.exercise_date: Each Common Warrant will be exercisable by the holder at any time on or after July 1, 2024 at an exercise price equal to $5.00 per share, subject to adjustments as provided under the terms of the Common Warrant, subject to a post-exercise beneficial ownership limitation of 4.99%. F2 · derivative.expiration_date: The Common Warrants expire on July 1, 2029. F3 · ownership.direct: On July 2, 2024, the Reporting Person mistakenly filed a Form 4 reporting the acquisition of an additional 150,000 Common Warrants and 150,000 Pre-Funded Warrants. The Reporting Person is not the beneficial owner of such Common Warrants or Pre-Funded Warrants. As of January 2, 2025, the Reporting Person owned only the Common Warrants and Pre-Funded Warrants reported herein. Read SEC document |
| December 28, 2023 Filed Dec 29, 2023 22:05 UTC | Elicio Therapeutics, Inc. ELTX · Entity 299 | GrantStock Option (right to buy) · Derivative | 4,100 | $0.00 Strike: $8.26 | $0.00 |
DisclosureSEC source: 0001140361-23-060235 · form4.xml · derivative · entry 1 Venkatesan Jay · CIK 0001413350 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,100 Underlying: Common Stock · 4,100 shares Expires 2033-12-28 F1 · shares: The stock option, granted in lieu of the annual equity award under the Issuer's Amended and Restated Non-Employee Director Compensation Policy, vests in full on the earlier of (A) December 28, 2024, the one-year anniversary of the grant date, or (B) immediately prior to the next annual meeting of the Issuer's stockholders, subject to the Reporting Person continuing to provide services to the Issuer through such vesting date. F1 · derivative.exercise_date: The stock option, granted in lieu of the annual equity award under the Issuer's Amended and Restated Non-Employee Director Compensation Policy, vests in full on the earlier of (A) December 28, 2024, the one-year anniversary of the grant date, or (B) immediately prior to the next annual meeting of the Issuer's stockholders, subject to the Reporting Person continuing to provide services to the Issuer through such vesting date. Read SEC document |
| July 15, 2022 Filed Jul 19, 2022 20:38 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | Exercise / conversionStock Option (Right to buy) · Derivative | 20,063 | $0.45 Strike: $0.45 | $9,028.35 |
DisclosureSEC source: 0001626199-22-000052 · wf-form4_165826307798060.xml · derivative · entry 5 Venkatesan Jay · CIK 0001413350 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 20,063 shares Expires 2025-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Pursuant to that certain Agreement and Plan of Merger and Reorganization (the "Merger Agreement"), dated as of April 18, 2017, by and among the Issuer, Nautilus Merger Sub, Inc. and the corporation then known as Alpine Immune Sciences, Inc. ("Old Alpine"), each share of Old Alpine common stock was converted into 0.4969 shares of the Issuer's common stock (the "Exchange Ratio"). Each option to purchase shares of Old Alpine outstanding and unexercised was assumed by the Issuer pursuant to the Merger Agreement and converted into an option, subject to vesting, to purchase shares of common stock of the Issuer, with the number of shares of the Issuer's common stock underlying such option and the exercise price for such option adjusted to reflect the Exchange Ratio. F5 · derivative.exercise_date: The Reporting Person was initially granted an option to acquire 300,000 shares, 75,000 shares of which vested on May 25, 2016, and the remaining shares vested or vest in 36 substantially equal monthly installments starting on September 1, 2016, subject to the Reporting person's continued service with the Issuer and certain change of control provisions. Read SEC document |
| July 15, 2022 Filed Jul 19, 2022 20:38 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | Exercise / conversionCommon Stock | 20,063 | $0.45 | $9,028.35 |
DisclosureSEC source: 0001626199-22-000052 · wf-form4_165826307798060.xml · nonDerivative · entry 4 Venkatesan Jay · CIK 0001413350 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 238,126 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 25, 2022 Filed May 27, 2022 20:18 UTC | Elicio Therapeutics, Inc. ANGN · Entity 299 | PurchaseCommon Stock | 11,313 | $1.25 | $14,102.79 |
DisclosureSEC source: 0001601485-22-000043 · wf-form4_165368268236817.xml · nonDerivative · entry 1 Venkatesan Jay · CIK 0001413350 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,891,947 Read SEC document |
| May 24, 2022 Filed May 25, 2022 21:58 UTC | Elicio Therapeutics, Inc. ANGN · Entity 299 | PurchaseCommon Stock | 32,200 | $1.24 | $39,928.00 |
DisclosureSEC source: 0001601485-22-000039 · wf-form4_165351588830337.xml · nonDerivative · entry 2 Venkatesan Jay · CIK 0001413350 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,721,457 Read SEC document |
| May 20, 2022 Filed May 25, 2022 21:58 UTC | Elicio Therapeutics, Inc. ANGN · Entity 299 | PurchaseCommon Stock | 50,000 | $1.23 | $61,500.00 |
DisclosureSEC source: 0001601485-22-000039 · wf-form4_165351588830337.xml · nonDerivative · entry 1 Venkatesan Jay · CIK 0001413350 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,689,257 Read SEC document |
| March 03, 2022 Filed Mar 4, 2022 21:22 UTC | Elicio Therapeutics, Inc. ANGN · Entity 299 | GrantStock Option (Right to Buy) · Derivative | 160,000 | $0.00 Strike: $1.94 | $0.00 |
DisclosureSEC source: 0001601485-22-000014 · wf-form4_164642894442998.xml · derivative · entry 2 Venkatesan Jay · CIK 0001413350 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 760,000 Underlying: Common Stock · 160,000 shares Expires 2032-03-02 F2 · derivative.exercise_date: The total number of options vest in equal parts on July 31, 2022 and December 31, 2022, such that 100% of the options will be fully vested and exercisable on December 31, 2022. Read SEC document |
| March 03, 2022 Filed Mar 4, 2022 21:22 UTC | Elicio Therapeutics, Inc. ANGN · Entity 299 | GrantStock Option (Right to Buy) · Derivative | 600,000 | $0.00 Strike: $1.94 | $0.00 |
DisclosureSEC source: 0001601485-22-000014 · wf-form4_164642894442998.xml · derivative · entry 1 Venkatesan Jay · CIK 0001413350 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 600,000 Underlying: Common Stock · 600,000 shares Expires 2032-03-02 F1 · derivative.exercise_date: The total number of options vest in forty-eight (48) successive and equal monthly installments as measured from March 3, 2022 (the "Vesting Commencement Date"), such that 100% of the options will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| January 03, 2022 Filed Jan 4, 2022 22:37 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | GrantStock Option (Right to buy) · Derivative | 10,000 | $0.00 Strike: $13.89 | $0.00 |
DisclosureSEC source: 0001626199-22-000016 · wf-form4_164133579169890.xml · derivative · entry 1 Venkatesan Jay · CIK 0001413350 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2032-01-02 F1 · derivative.exercise_price: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F2 · derivative.exercise_date: 1/12th of the shares subject to the option become vested and exercisable on February 3, 2022 and 1/12th of the shares subject to the option shall vest monthly thereafter. Read SEC document |
| December 28, 2021 Filed Dec 29, 2021 21:08 UTC | Elicio Therapeutics, Inc. ANGN · Entity 299 | PurchaseCommon Stock | 210,337 | $2.66 | $559,853.99 |
DisclosureSEC source: 0001601485-21-000095 · wf-form4_164081206871822.xml · nonDerivative · entry 2 Venkatesan Jay · CIK 0001413350 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,639,257 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.55 to $2.75 inclusive. Read SEC document |
| December 27, 2021 Filed Dec 29, 2021 21:08 UTC | Elicio Therapeutics, Inc. ANGN · Entity 299 | PurchaseCommon Stock | 66,907 | $2.55 | $170,519.18 |
DisclosureSEC source: 0001601485-21-000095 · wf-form4_164081206871822.xml · nonDerivative · entry 1 Venkatesan Jay · CIK 0001413350 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,428,920 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.54 to $2.55 inclusive. Read SEC document |
| December 20, 2021 Filed Dec 22, 2021 21:06 UTC | Elicio Therapeutics, Inc. ANGN · Entity 299 | PurchaseCommon Stock | 3,527 | $2.54 | $8,975.86 |
DisclosureSEC source: 0001601485-21-000093 · wf-form4_164020718382276.xml · nonDerivative · entry 1 Venkatesan Jay · CIK 0001413350 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,362,013 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.52 to $2.55 inclusive. Read SEC document |
| December 17, 2021 Filed Dec 20, 2021 23:44 UTC | Elicio Therapeutics, Inc. ANGN · Entity 299 | PurchaseCommon Stock | 13,742 | $2.54 | $34,958.27 |
DisclosureSEC source: 0001601485-21-000089 · wf-form4_164004385539278.xml · nonDerivative · entry 2 Venkatesan Jay · CIK 0001413350 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,358,486 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.50 to $2.55 inclusive. Read SEC document |
| December 16, 2021 Filed Dec 20, 2021 23:44 UTC | Elicio Therapeutics, Inc. ANGN · Entity 299 | PurchaseCommon Stock | 27,883 | $2.55 | $70,992.91 |
DisclosureSEC source: 0001601485-21-000089 · wf-form4_164004385539278.xml · nonDerivative · entry 1 Venkatesan Jay · CIK 0001413350 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,344,744 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.53 to $2.55 inclusive. Read SEC document |
| December 15, 2021 Filed Dec 17, 2021 22:13 UTC | Elicio Therapeutics, Inc. ANGN · Entity 299 | PurchaseCommon Stock | 77,604 | $2.41 | $186,955.80 |
DisclosureSEC source: 0001601485-21-000087 · wf-form4_163977918794672.xml · nonDerivative · entry 2 Venkatesan Jay · CIK 0001413350 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,316,861 Read SEC document |
| September 17, 2021 Filed Sep 21, 2021 21:14 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | SaleCommon Stock | 400,000 | $9.40 | $3,760,000.00 |
DisclosureSEC source: 0001626199-21-000113 · wf-form4_163225883908242.xml · nonDerivative · entry 1 Venkatesan Jay · CIK 0001413350 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Alpine ImmunoSciences, L.P. Disclosed balance after: 2,600,980 F1 · shares: These shares were sold in a private transaction to an investor in the Issuer simultaneously with the closing of the Issuer's private placement on September 17, 2021. F2 · ownership.nature: The Reporting Person disclaims beneficial ownership of the shares of common stock reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F3 · ownership.nature: Alpine BioVentures GP, LLC is the general partner of Alpine ImmunoSciences, L.P. Dr. Venkatesan is a Managing Partner of Alpine BioVenture GP, LLC. Dr. Venkatesan is also a limited partner of Alpine ImmunoSciences, L.P. By virtue of such relationships, Dr. Venkatesan may be deemed to have voting and investment power with respect to the shares held by Alpine ImmunoSciences, L.P. and as a result may be deemed to have beneficial ownership of such shares. Read SEC document |
| June 24, 2021 Filed Dec 17, 2021 22:13 UTC | Elicio Therapeutics, Inc. ANGN · Entity 299 | Tax withholdingCommon Stock | 41,091 | $13.78 | $566,233.98 |
DisclosureSEC source: 0001601485-21-000087 · wf-form4_163977918794672.xml · nonDerivative · entry 1 Venkatesan Jay · CIK 0001413350 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,239,257 F1 · kind: The shares were withheld to satisfy tax or other government withholding obligations in connection with the vesting of Restricted Stock Units ("RSUs"). Read SEC document |
| March 31, 2021 Filed Apr 23, 2021 22:14 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | Exercise / conversionStock Option (Right to buy) · Derivative | 7,650 | $0.00 Strike: $3.62 | $0.00 |
DisclosureSEC source: 0001626199-21-000044 · wf-form4_161921602524556.xml · derivative · entry 7 Venkatesan Jay · CIK 0001413350 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,650 shares Expires 2030-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The shares subject to the option became fully vested and exercisable on January 2, 2021. Read SEC document |
| March 31, 2021 Filed Apr 23, 2021 22:14 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | Exercise / conversionCommon Stock | 7,650 | $3.62 | $27,718.25 |
DisclosureSEC source: 0001626199-21-000044 · wf-form4_161921602524556.xml · nonDerivative · entry 2 Venkatesan Jay · CIK 0001413350 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 218,063 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 30, 2021 Filed Apr 23, 2021 22:14 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | Exercise / conversionStock Option (Right to buy) · Derivative | 7,650 | $0.00 Strike: $4.09 | $0.00 |
DisclosureSEC source: 0001626199-21-000044 · wf-form4_161921602524556.xml · derivative · entry 6 Venkatesan Jay · CIK 0001413350 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,650 shares Expires 2029-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares subject to the option became fully vested and exercisable on January 2, 2020. Read SEC document |
| March 30, 2021 Filed Apr 23, 2021 22:14 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | Exercise / conversionCommon Stock | 7,650 | $4.09 | $31,288.50 |
DisclosureSEC source: 0001626199-21-000044 · wf-form4_161921602524556.xml · nonDerivative · entry 1 Venkatesan Jay · CIK 0001413350 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 210,413 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 09, 2021 Filed Feb 12, 2021 00:25 UTC | Elicio Therapeutics, Inc. ANGN · Entity 299 | ConversionConvertible Promissory Note · Derivative | Not disclosed | $0.00 Strike: $16.00 | $3,138.90 |
DisclosureSEC source: 0001567619-21-003193 · doc1.xml · derivative · entry 8 Venkatesan Jay · CIK 0001413350 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · Not disclosed shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The convertible promissory note converted immediately prior to the consummation of the IPO into Common Stock. F6 · derivative.expiration_date: The convertible promissory note ("Convertible Note") had a maturity date of August 14, 2021 and the principal amount of the Convertible Note converted upon the closing of the IPO into Common Shares at a conversion price equal to $18.00 per Common Share. Read SEC document |
| February 09, 2021 Filed Feb 12, 2021 00:25 UTC | Elicio Therapeutics, Inc. ANGN · Entity 299 | OtherWarrant to Purchase Common Stock · Derivative | 237,152 | $0.00 Strike: $6.43 | $0.00 |
DisclosureSEC source: 0001567619-21-003193 · doc1.xml · derivative · entry 7 Venkatesan Jay · CIK 0001413350 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 237,152 shares Expires 2028-07-05 F4 · derivative.exercise_date: On February 9, 2021 the Reporting Person exercised a warrant to purchase an aggregate of 396,328 shares of the Issuer's common stock for $16.00 a share, which represents the Issuer's IPO price. In connection with the automatic net exercise of the warrant immediately prior to the closing of the Issuer's IPO, the Issuer withheld 159,177 of the warrant shares to pay the exercise price and issued the remaining 237,152 shares of common stock to Reporting Person. Read SEC document |
| February 09, 2021 Filed Feb 12, 2021 00:25 UTC | Elicio Therapeutics, Inc. ANGN · Entity 299 | ConversionSeries C Cumulative Convertible Preferred · Derivative | 1,804 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-003193 · doc1.xml · derivative · entry 6 Venkatesan Jay · CIK 0001413350 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,804 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each share of the issuer's Series C Preferred Stock automatically converted into 91.52 shares of the issuer's Common Stock immediately prior to the consummation of the issuer's IPO and had no expiration date. F3 · derivative.exercise_date: Each share of the issuer's Series C Preferred Stock automatically converted into 91.52 shares of the issuer's Common Stock immediately prior to the consummation of the issuer's IPO and had no expiration date. F3 · derivative.expiration_date: Each share of the issuer's Series C Preferred Stock automatically converted into 91.52 shares of the issuer's Common Stock immediately prior to the consummation of the issuer's IPO and had no expiration date. Read SEC document |
| February 09, 2021 Filed Feb 12, 2021 00:25 UTC | Elicio Therapeutics, Inc. ANGN · Entity 299 | ConversionCommon Stock | 262 | $11.57 | $3,031.34 |
DisclosureSEC source: 0001567619-21-003193 · doc1.xml · nonDerivative · entry 5 Venkatesan Jay · CIK 0001413350 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,280,348 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · balance_after: Includes 246,299 RSUs. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof. Read SEC document |
| February 09, 2021 Filed Feb 12, 2021 00:25 UTC | Elicio Therapeutics, Inc. ANGN · Entity 299 | SaleCommon Stock | 159,177 | $16.00 | $2,546,832.00 |
DisclosureSEC source: 0001567619-21-003193 · doc1.xml · nonDerivative · entry 4 Venkatesan Jay · CIK 0001413350 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,208,086 F2 · balance_after: Includes 246,299 RSUs. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof. F4 · balance_after: On February 9, 2021 the Reporting Person exercised a warrant to purchase an aggregate of 396,328 shares of the Issuer's common stock for $16.00 a share, which represents the Issuer's IPO price. In connection with the automatic net exercise of the warrant immediately prior to the closing of the Issuer's IPO, the Issuer withheld 159,177 of the warrant shares to pay the exercise price and issued the remaining 237,152 shares of common stock to Reporting Person. Read SEC document |
| February 09, 2021 Filed Feb 12, 2021 00:25 UTC | Elicio Therapeutics, Inc. ANGN · Entity 299 | OtherCommon Stock | 237,152 | $6.43 | $1,524,887.36 |
DisclosureSEC source: 0001567619-21-003193 · doc1.xml · nonDerivative · entry 3 Venkatesan Jay · CIK 0001413350 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,439,263 F2 · balance_after: Includes 246,299 RSUs. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof. F4 · balance_after: On February 9, 2021 the Reporting Person exercised a warrant to purchase an aggregate of 396,328 shares of the Issuer's common stock for $16.00 a share, which represents the Issuer's IPO price. In connection with the automatic net exercise of the warrant immediately prior to the closing of the Issuer's IPO, the Issuer withheld 159,177 of the warrant shares to pay the exercise price and issued the remaining 237,152 shares of common stock to Reporting Person. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.